Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058895 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL5058893 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL4192293 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963007 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175205 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963002 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747719 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747720 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747717 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175204 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-107709295-B | Tricyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2021-05-04 | — | — | CN | disclosed |
| US-5668164-A | Process for synthesis of chiral cis-and trans-3-amino-4 substituted pyrrolidine compounds | ABBOTT LABORATORIES (US) | 1997-09-16 | — | — | US | disclosed |
| US-5618949-A | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds | ABBOTT LABORATORIES (US) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | NAAA 3516/4885ABCB1 4141/4885FAAH 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.